阿司匹林
医学
肾脏疾病
安慰剂
肾功能
重症监护医学
疾病
随机对照试验
临床试验
析因分析
子群分析
肾
内科学
心脏病学
病理
替代医学
荟萃分析
作者
Pavel S Roshanov,Amit X. Garg
标识
DOI:10.1016/j.kint.2022.10.018
摘要
Aspirin effectively prevents subsequent cardiovascular events. A post hoc subgroup analysis of the International Polycap Study 3 (TIPS-3) trial suggests that patients with chronic kidney disease might also benefit from aspirin for primary prevention. We consider the merits of doing so in practice. Aspirin effectively prevents subsequent cardiovascular events. A post hoc subgroup analysis of the International Polycap Study 3 (TIPS-3) trial suggests that patients with chronic kidney disease might also benefit from aspirin for primary prevention. We consider the merits of doing so in practice. Effects of aspirin on cardiovascular outcomes in patients with chronic kidney diseaseKidney InternationalVol. 103Issue 2PreviewPatients with chronic kidney disease (CKD) carry a high cardiovascular (CV) risk. Since whether this risk is reduced by aspirin is unclear, we examined if the effect of aspirin on cardiovascular outcomes varied by baseline kidney function in a primary cardiovascular disease prevention trial. The International Polycap Study-3 (TIPS-3) trial had randomized people without previous cardiovascular disease to aspirin (75 mg daily) or placebo. We now examined aspirin versus placebo on cardiovascular events in participants grouped by estimated glomerular filtration rate (eGFR), using a threshold of 60 ml/min/1.73 m2, and by using tertiles of eGFR. Full-Text PDF
科研通智能强力驱动
Strongly Powered by AbleSci AI